Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion in assets and a 0.06% expense ratio. SCHD currently yields roughly 3.3% and has delivered a 20% year-to-date price return on top of income, outpacing the S&P 500. The key question is whether the distribution is durable, and the answer lies in the fund’s top holdings.
How SCHD Builds Its Income Stream
SCHD tracks the Dow Jones U.S. Dividend 100 Index, a rules-based screen filtering for cash flow to total debt, return on equity, dividend yield, and five-year dividend growth. The result is 100 mature, cash-generating businesses weighted roughly equally at the top: the largest 10 positions each represent roughly 4% of assets. That balance protects income safety. No single dividend cut would gut the distribution.
The income is straightforward: dividends from underlying companies pass directly to shareholders as ordinary cash distributions.
The Top Holdings Doing the Heavy Lifting
Bristol Myers Squibb is the largest position at 4%. The quarterly payout stepped up to $0.63 in 2026, and Q1 revenue rose 3% to $11.49 billion as the Growth Portfolio (Eliquis, Camzyos, Breyanzi) absorbed legacy declines. With a trailing P/E of 16 and an analyst target of $63, the dividend is well covered against TTM EPS of $3.57.
Lockheed Martin and Chevron warrant closer inspection. Lockheed’s Q1 free cash flow swung to negative $291 million on F-16, C-130, and CH-53K program charges, yet management reaffirmed full-year FCF guidance of $6.5 to $6.8 billion, comfortably above the dividend. Chevron posted negative FCF in Q1 but raised its quarterly payout to $1.78 and executed $2.5 billion in buybacks. Both are Dividend Aristocrats with strong balance sheets: Chevron’s net debt/EBITDA of 1.08 and interest coverage of 13.7 can absorb a soft quarter.
Coca-Cola is the cleanest story. Q1 free cash flow rose 132% year over year, comparable EPS guidance points to 8% to 9% growth on a 2025 base of $3.00, and the quarterly dividend stepped up to $0.53. A payout near two-thirds of TTM EPS of $3.18 leaves room for further increases.
AbbVie requires explanation. Humira sales fell 39% on biosimilar pressure, but Skyrizi (+31%) and Rinvoq (+23%) offset the decline. Management raised 2026 adjusted EPS guidance to $14.08 to $14.28, funding the $6.74 annual dividend. The trailing GAAP P/E of 105 reflects a one-time charge; the forward P/E of 15 is the cleaner metric.
Verizon carries the highest yield at 5.7% and the most debt at $144 billion. The Q2 2026 payout rose to $0.7075, marking 19 straight years of increases. Free cash flow of nearly $20 billion covers the dividend, though rising interest expense warrants monitoring.
Total Return, Not Just Yield
SCHD has returned 53% over five years and 237% over ten, trailing growth-tilted peers but holding its own against dividend alternatives. Vanguard High Dividend Yield ETF returned 72% over five years with broader diversification but lower yield, while iShares Core Dividend Growth ETF returned 65% over the same span. SCHD’s edge is yield-plus-quality at a 0.06% fee.
The Verdict on SCHD’s Distribution
The distribution is safe. Every top holding is a Dividend Aristocrat or long-streak grower, free cash flow covers payouts across the basket, and equal weighting at the top means no single cut would meaningfully dent income. For investors seeking growing income from real cash-flowing businesses, this fund earns its popularity.
Top Gaining Stocks
Top Losing Stocks